CSF-1 inhibitors have shown to deter glioma recurrence after radiation in vivo (91), prevent radiation-induced cognitive impairment in preclinical models (92, 93), and are well-tolerated in clinical trials (94). The gene discussed is CSF1; the disease is glioma.